Eli Lilly Poised for Massive Growth with Diabetes, Obesity Drugs and Potential Alzheimer's Blockbuster

Eli Lilly is a top biotech company with huge growth potential, especially in diabetes and obesity care.
Its new drug Mounjaro is already generating almost $1 billion in sales just a year after approval.
Obesity drug market projected to reach $100 billion by 2030, benefiting Eli Lilly.
Alzheimer's drug donanemab could produce $2.1 billion in sales by 2028 if approved.
Revenue grew 22% last quarter excluding COVID-19 drugs, showing underlying business strength.

fool.com

Relevant topic timeline:

9/7/2023

Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says. That Makes Eli Lilly Stock a Big Winner.

Eli Lilly could potentially generate $50 billion in annual sales from weight-loss drugs by 2030, positioning the pharmaceutical company as a major beneficiary in the obesity treatment market, according to J.P. Morgan.

9/19/2023

Eli Lilly Sues Providers Over Unauthorized Sales of Diabetes Drug Mounjaro Amid Shortage

Eli Lilly has sued 10 medical spas, wellness clinics, and compounding pharmacies across the U.S. for allegedly selling unauthorized versions of its diabetes drug Mounjaro, as the company faces a shortage of the drug due to high demand and its off-label use for weight loss.

10/3/2023

Lilly to Acquire POINT Biopharma for $1.4 Billion, Gaining Radioligand Cancer Therapies

Eli Lilly will acquire POINT Biopharma, a radiopharmaceutical company, in a deal worth $1.4 billion, aiming to develop radioligand therapies for cancer treatment by precisely targeting cancer cells while limiting damage to healthy tissue.

10/12/2023

Eli Lilly Soars on Diabetes Drug Success and Promising Obesity Treatment

Shares of pharmaceutical company Eli Lilly are on the rise, driven by the growth potential of its diabetes and obesity products, leading analysts to predict that it could become the first trillion-dollar bio-pharma company. The company's recent approval of Mounjaro for treating type 2 diabetes has resulted in strong revenue growth, and there is anticipation that it will also gain FDA approval for treating obesity. Wall Street analysts are optimistic about Eli Lilly stock, with a consensus rating of Strong Buy.

Topics

Posted 9/16/2023, 11:15:00 AM